Kevin J Yeaman sold $2.2M of DLB
President and CEO at Dolby Laboratories, Inc.. 33,517 shares at an average of $66.84, traded Dec 16, 2025, filed Dec 17, 2025.
Score components
- +25RoleCEO
- +25Trade size$2.2M at market
- +10Share of holdings soldSold 25% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.9%, 3m -8.9%, 6m -22.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-323431, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 15, 2025 | AGrant or award Class A Common Stock10b5-1 | +65,968 | $0.00 | $0 | 193,703 | Dec 17, 2025 |
| Dec 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +17,633 | $0.00 | $0 | 202,587 | Dec 17, 2025 |
| Dec 15, 2025 | FTax withholding Class A Common Stock10b5-1 | -27,180 | $67.54 | $1.8M | 157,390 | Dec 17, 2025 |
| Dec 16, 2025 | FTax withholding Class A Common Stock10b5-1 | -6,855 | $66.62 | $457k | 143,784 | Dec 17, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stockindirect: By a trust10b5-1 | -21,772 | $66.64 | $1.5M | 110,122 | Dec 17, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stockindirect: By a trust10b5-1 | -4,994 | $67.16 | $335k | 105,128 | Dec 17, 2025 |
| Dec 17, 2025 | SOpen-market sale Class A Common Stockindirect: By a trust10b5-1 | -6,671 | $67.24 | $449k | 98,457 | Dec 17, 2025 |
| Dec 17, 2025 | SOpen-market sale Class A Common Stockindirect: By a trust10b5-1 | -80 | $67.54 | $5,403 | 98,377 | Dec 17, 2025 |
| Dec 15, 2025 | AGrant or award Performance-Based Restricted Stock Unitderivative10b5-1 | +32,984 | $0.00 | $0 | 32,984 | Dec 17, 2025 |
| Dec 15, 2025 | AGrant or award Employee Stock Option (Right to Buy)derivative10b5-1 | +145,252 | $0.00 | $0 | 145,252 | Dec 17, 2025 |
| Dec 15, 2025 | MOption exercise Performance-Based Restricted Stock Unitderivative10b5-1 | -17,633 | $0.00 | $0 | 0 | Dec 17, 2025 |
Related signals
Other insiders at Dolby Laboratories, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Dolby Laboratories, Inc. | John D Couling SVP, Entertainment | $451k 7,667 shares | -4% | |
| 5Weak | Dolby Laboratories, Inc. | John D Couling SVP, Entertainment | $468k 7,667 shares | -6% | |
| 38Weak | Dolby Laboratories, Inc. | Ryan Nicholson VP, CAO and Corp. Controller | $77k 1,183 shares | -3% | |
| 22Weak | Dolby Laboratories, Inc. | Shriram Revankar SVP, Advanced Technology Group | $188k 3,000 shares | -4% | |
| 39Weak | Dolby Laboratories, Inc. | Ryan Nicholson VP, CAO and Corp. Controller | $84k 1,348 shares | -4% | |
| 30Weak | Dolby Laboratories, Inc. | Ryan Nicholson VP, CAO and Corp. Controller | $22k 357 shares | -1% | |
| 12Weak | Dolby Laboratories, Inc. | John D Couling SVP, Entertainment | $460k 7,667 shares | -6% | |
| 0Weak | Dolby Laboratories, Inc. | John D Couling SVP, Entertainment | $408k 7,667 shares | -6% | |
| 5Weak | Dolby Laboratories, Inc. | John D Couling SVP, Entertainment | $426k 7,666 shares | -6% | |
| 55Moderate | Dolby Laboratories, Inc. | Todd Pendleton SVP, Chief Marketing Officer | $648k 11,876 shares | -22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.